分享到朋友圈
13
15
31
1871
0
Current Standard Practice after ASCO 2021: Gastrointestinal Cancer
中国抗肿瘤药物的创新之路
结直肠癌免疫治疗探索之路
讨论-11
抗肿瘤创新药二期临床实验设计的实践
评价TQB2450 注射液在中国晚期恶性肿瘤患者的安全性和耐受性：来自TQB2450 注射液耐受性和药代动力学I 期临床研究的初步数据分析
自主发起的临床研究的设计要点
新药临床实验不良事件管理策略
Current Standard Practice after ASCO 2019: Gastrointestinal Cancer
GR007-CT02:评价注射用重组人白介素-1受体拮抗剂在接受FOLFIRI化疗方案的恶性肿瘤患者中的安全性、耐受性、药代动力学特征的剂量递增、单中心、开放的Ⅰb期临床试验研究
FRESCO研究：呋喹替尼对比安慰剂在经治的转移性结直肠癌患者中对总生存的影响
A Multi-Center, Open-Label, and Dose-Expansion Phase Ib Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb): Preliminary Results from CS1001 in Combination with Cisplatin and 5-Fluorouracil (CF) Chemotherapy in Patie
HLX04, A Bevacizumab Biosimilar, Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: A Phase III Study
北京市希思科临床肿瘤学研究基金会理事长致辞
A Phase I/IIa, Open-label, Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients with Advanced Solid Tumors
